Literature DB >> 1862078

v-abl causes hematopoietic disease distinct from that caused by bcr-abl.

M L Scott1, R A Van Etten, G Q Daley, D Baltimore.   

Abstract

v-abl, the oncogene transduced by Abelson murine leukemia virus, was first characterized by its ability to transform lymphoid cells. bcr-abl, the oncogene formed by a t(9;22) translocation thought to occur in human hematopoietic stem cells, is detectable in almost all cases of chronic myelogenous leukemia (CML), a malignancy of granulocytic cells. bcr-abl also causes a CML-like syndrome in mice whose bone-marrow cells are infected with a retrovirus transducing the gene. More recent reports have suggested that v-abl can, however, cause a disease similar to CML. We demonstrate here that v-abl, when transduced in a helper virus-containing system, causes disease similar to, but distinct from, the CML-like syndrome induced by bcr-abl. Animals whose bone marrow has been infected by v-abl virus develop modest splenomegaly, marked granulocytosis, and malignant disease of several hematopoietic cell types. Unlike animals with CML-like disease resulting from bcr-abl, the polymorphonuclear leukocytes from animals infected with a v-abl construct do not contain the v-abl provirus at a significant frequency. Histopathologic analysis also shows significant differences between the diseases caused by v-abl and bcr-abl.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1862078      PMCID: PMC52114          DOI: 10.1073/pnas.88.15.6506

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity.

Authors:  B J Mayer; P K Jackson; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

Review 2.  Chronic myelogenous leukemia: recent advances.

Authors:  R E Champlin; D W Golde
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

3.  Identification of a novel bone marrow-derived B-cell progenitor population that coexpresses B220 and Thy-1 and is highly enriched for Abelson leukemia virus targets.

Authors:  G F Tidmarsh; S Heimfeld; C A Whitlock; I L Weissman; C E Müller-Sieburg
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

4.  The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization.

Authors:  R A Van Etten; P Jackson; D Baltimore
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

5.  Lymphosarcoma: virus-induced thymic-independent disease in mice.

Authors:  H T Abelson; L S Rabstein
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

Review 6.  The viral and cellular forms of the Abelson (abl) oncogene.

Authors:  N Rosenberg; O N Witte
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

7.  Protein stabilization explains the gag requirement for transformation of lymphoid cells by Abelson murine leukemia virus.

Authors:  R Prywes; J Hoag; N Rosenberg; D Baltimore
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

8.  The minimum transforming region of v-abl is the segment encoding protein-tyrosine kinase.

Authors:  R Prywes; J G Foulkes; D Baltimore
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

9.  Expression cloning of the murine erythropoietin receptor.

Authors:  A D D'Andrea; H F Lodish; G G Wong
Journal:  Cell       Date:  1989-04-21       Impact factor: 41.582

10.  Transformation of T-lymphoid cells by Abelson murine leukemia virus.

Authors:  M L Scott; M M Davis; M B Feinberg
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

View more
  10 in total

1.  V(D)J recombination is not activated by demethylation of the kappa locus.

Authors:  S R Cherry; C Beard; R Jaenisch; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

2.  Production of high-titer helper-free retroviruses by transient transfection.

Authors:  W S Pear; G P Nolan; M L Scott; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

3.  Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.

Authors:  A W Gross; X Zhang; R Ren
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

Review 4.  Models of chronic myeloid leukemia.

Authors:  R A Van Etten
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

5.  Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton.

Authors:  Sajjad Hossain; Patrycja M Dubielecka; Aleksander F Sikorski; Raymond B Birge; Leszek Kotula
Journal:  Genes Cancer       Date:  2012-05

6.  BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.

Authors:  S S Clark; E Chen; M Fizzotti; O N Witte; V Malkovska
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

7.  E2a/Pbx1 induces the rapid proliferation of stem cell factor-dependent murine pro-T cells that cause acute T-lymphoid or myeloid leukemias in mice.

Authors:  David B Sykes; Mark P Kamps
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

8.  Signaling by ABL oncogenes through cyclin D1.

Authors:  D E Afar; J McLaughlin; C J Sherr; O N Witte; M F Roussel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

9.  The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Authors:  S Li; R L Ilaria; R P Million; G Q Daley; R A Van Etten
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

10.  Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.

Authors:  W S Pear; J C Aster; M L Scott; R P Hasserjian; B Soffer; J Sklar; D Baltimore
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.